The Jewish Exponent reports on the recent controversial study by the U.S. Preventative Services Task Force questioning the use of a prostate-specific antigen (PSA) test in saving the lives of those with prostate cancer. The American Association of Clinical Urologists and American Urological Association "are vigorously opposed to a blanket recommendation against screening," explains Alan Wein, MD, chair of the division of Urology. "On a personal basis, I am against the findings and the D-1 rating they assigned against PSA blood tests as well," said Wein, about the rating that marks when the cancer has entered the lymph nodes only.
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
